These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19090993)

  • 1. Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors.
    Wisniewski T; Sadowski M
    BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S5. PubMed ID: 19090993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo.
    Hong HS; Rana S; Barrigan L; Shi A; Zhang Y; Zhou F; Jin LW; Hua DH
    J Neurochem; 2009 Feb; 108(4):1097-1108. PubMed ID: 19141069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy.
    Soto C; Saborio GP; Permanne B
    Acta Neurol Scand Suppl; 2000; 176():90-5. PubMed ID: 11261811
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Jean L; Brimijoin S; Vaux DJ
    J Biol Chem; 2019 Apr; 294(16):6253-6272. PubMed ID: 30787102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
    Wisniewski T; Boutajangout A
    Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-sheet breakers for Alzheimer's disease therapy.
    Bieler S; Soto C
    Curr Drug Targets; 2004 Aug; 5(6):553-8. PubMed ID: 15270201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid.
    Kanekiyo T; Ban T; Aritake K; Huang ZL; Qu WM; Okazaki I; Mohri I; Murayama S; Ozono K; Taniike M; Goto Y; Urade Y
    Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6412-7. PubMed ID: 17404210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Sheet secondary structure in amyloid β-peptide drives aggregation and toxicity in Alzheimer's disease.
    Shea D; Hsu CC; Bi TM; Paranjapye N; Childers MC; Cochran J; Tomberlin CP; Wang L; Paris D; Zonderman J; Varani G; Link CD; Mullan M; Daggett V
    Proc Natl Acad Sci U S A; 2019 Apr; 116(18):8895-8900. PubMed ID: 31004062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity.
    Wilhelmus MM; Boelens WC; Otte-Höller I; Kamps B; Kusters B; Maat-Schieman ML; de Waal RM; Verbeek MM
    Acta Neuropathol; 2006 Feb; 111(2):139-49. PubMed ID: 16485107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid binding ligands as Alzheimer's disease therapies.
    Lee VM
    Neurobiol Aging; 2002; 23(6):1039-42. PubMed ID: 12470800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid inhibitors and beta-sheet breakers.
    Soto C; Estrada L
    Subcell Biochem; 2005; 38():351-64. PubMed ID: 15709488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TDP-43 interacts with amyloid-β, inhibits fibrillization, and worsens pathology in a model of Alzheimer's disease.
    Shih YH; Tu LH; Chang TY; Ganesan K; Chang WW; Chang PS; Fang YS; Lin YT; Jin LW; Chen YR
    Nat Commun; 2020 Nov; 11(1):5950. PubMed ID: 33230138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.
    Watson D; Castaño E; Kokjohn TA; Kuo YM; Lyubchenko Y; Pinsky D; Connolly ES; Esh C; Luehrs DC; Stine WB; Rowse LM; Emmerling MR; Roher AE
    Neurol Res; 2005 Dec; 27(8):869-81. PubMed ID: 16354549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization.
    De Felice FG; Vieira MN; Saraiva LM; Figueroa-Villar JD; Garcia-Abreu J; Liu R; Chang L; Klein WL; Ferreira ST
    FASEB J; 2004 Sep; 18(12):1366-72. PubMed ID: 15333579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abeta aggregation and possible implications in Alzheimer's disease pathogenesis.
    Bharadwaj PR; Dubey AK; Masters CL; Martins RN; Macreadie IG
    J Cell Mol Med; 2009 Mar; 13(3):412-21. PubMed ID: 19374683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Bio)chemical Strategies To Modulate Amyloid-β Self-Assembly.
    Ayala S; Genevaux P; Hureau C; Faller P
    ACS Chem Neurosci; 2019 Aug; 10(8):3366-3374. PubMed ID: 31265239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality?
    Talaga P
    Mini Rev Med Chem; 2001 Jul; 1(2):175-86. PubMed ID: 12369982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disrupting beta-amyloid aggregation for Alzheimer disease treatment.
    Estrada LD; Soto C
    Curr Top Med Chem; 2007; 7(1):115-26. PubMed ID: 17266599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease.
    Wilhelmus MM; de Waal RM; Verbeek MM
    Mol Neurobiol; 2007 Jun; 35(3):203-16. PubMed ID: 17917109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
    Yang F; Lim GP; Begum AN; Ubeda OJ; Simmons MR; Ambegaokar SS; Chen PP; Kayed R; Glabe CG; Frautschy SA; Cole GM
    J Biol Chem; 2005 Feb; 280(7):5892-901. PubMed ID: 15590663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.